Zacks Investment Research on MSN
Is State Street SPDR S&P Biotech ETF (XBI) a strong ETF right now?
The State Street SPDR S&P Biotech ETF (XBI) was launched on 01/31/2006, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market. What ...
Shares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than ...
24/7 Wall St. on MSN
Josh Brown: Biotech growth stocks immune to disruption risk
Quick Read Large-cap biotech stocks face patent cliffs and biosimilar competition rather than AI-driven disruption, but ...
FBT selects 30 biotechnology stocks based on sales, sales as a percentage of R&D expenditures, and R&D growth compared to three years ago. The ETF launched 19 years ago and has delivered exceptional ...
The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...
This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results